Top

07-11-2024 | Neuroblastoma | REVIEW ARTICLE

Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma

Authors: Raquel Sánchez-Vañó, Julia Balaguer, Isabel Borrego-Dorado, Alba Esteban-Figueruelo, Cristina Gámez, Raquel Hladun, Ricardo López-Almaraz, Mercedes L. Llempén, Sonia Rodado, Pedro M. Rubio-Aparicio

Published in: Clinical and Translational Oncology

Abstract

Neuroblastoma (NB) is the most common extracranial solid cancer in children. Despite intensive multimodality treatment, long-term survival of patients with high-risk NB, which comprises more than half of all cases, remains poor. Nuclear medicine is key in diagnosis, staging, response assessment and long-term follow-up of NB. The emergence of novel tracers and the increasing complexity of studies require updated guidelines for nuclear medicine imaging in NB. Standardising diagnostic techniques are essential for improving study comparability and ensuring test quality. This article aims to provide a comprehensive review of NB radionuclide diagnostic imaging, including its characteristics, accuracy, advantages, and limitations. It offers practical recommendations to multidisciplinary teams responsible for treating patients with NB. This review summarises the opinions of leading experts from the Neuroblastoma Spanish Group within the Spanish Society of Paediatric Haematology and Oncology (SEHOP) and the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM).

Available only for authorised users

Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B, et al. Neuroblastoma. Pediatr Blood Cancer. 2021;68(Suppl 2): e28473.PubMedPubMedCentralCrossRef

Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–11.PubMedPubMedCentralCrossRef

Samim A, Tytgat GAM, Bleeker G, Wenker STM, Chatalic KLS, Poot AJ, et al. Nuclear medicine imaging in neuroblastoma: current status and new developments. J Pers Med. 2021;11:270.PubMedPubMedCentralCrossRef

Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN High-risk Neuroblastoma 1 Trial (HR-NBL1). Cancers. 2020;12:309.PubMedPubMedCentralCrossRef

Gray J, Moreno L, Weston R, Barone G, Rubio A, Makin G, et al. BEACON-Immuno: results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. J Clin Oncol. 2022;40:10002–10002.CrossRef

Lode HN, Ehlert K, Huber S, Troschke-Meurer S, Siebert N, Zumpe M, et al. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study. Br J Cancer. 2023;129:1780–6.PubMedPubMedCentralCrossRef

PDQ Pediatric Treatment Editorial Board. Neuroblastoma Treatment (PDQ®): Health Professional Version. PDQ Cancer Inf Summ [Internet]. Bethesda (MD): National Cancer Institute (US); 2002 [cited 2023 May 16]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK65747/

Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009–24.PubMedCrossRef

SIOP Europe Imaging Working Group: SIOP Europe [Internet]. [cited 2023 Nov 8]. Available from: https://siope.eu/SIOP-Europe-Imaging-Working-Group/

10.

Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46.PubMedCrossRef

11.

Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261:243–57.PubMedCrossRef

12.

Protocolos diagnósticos y terapéuticos en Pediatría | Asociación Española de Pediatría [Internet]. [cited 2023 Jul 22]. Available from: https://www.aeped.es/protocolos

13.

SEHOP. Grupo de Neuroblastoma [Internet]. [cited 2023 Jul 22]. Available from: http://www.gruponeuroblastoma.es/

14.

EANM. Guidelines. Paediatric [Internet]. EANM. 2020 [cited 2023 Jul 22]. Available from: https://www.eanm.org/publications/guidelines/paediatrics/

15.

Clinical Guidelines - SNMMI [Internet]. [cited 2023 Jul 22]. Available from: https://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=10817

16.

International Neuroblastoma Risk Group Task Force [Internet]. [cited 2023 Jul 22]. Available from: https://inrgdb.org/

17.

COG. Neuroblastoma [Internet]. [cited 2023 Jul 22]. Available from: https://www.childrensoncologygroup.org/index.php/neuroblastoma

18.

SIOPEN-R-NET | Home [Internet]. [cited 2023 Jul 22]. Available from: https://www.siopen-r-net.org/

19.

https://www.cclg.org.uk/groups/neuroblastoma [Internet]. [cited 2023 Jul 22]. Available from: https://www.cclg.org.uk/groups/neuroblastoma

20.

The American Society of Pediatric Hematology/Oncology [Internet]. [cited 2023 Jul 22]. Available from: http://aspho.org/

21.

ESMO. Guidelines. ESMO. Guidelines [Internet]. [cited 2023 Jul 22]. Available from: https://www.esmo.org/guidelines

22.

ASCO. Guidelines, Tools, & Resources [Internet]. ASCO. [cited 2023 Jul 22]. Available from: https://old-prod.asco.org/practice-patients/guidelines

23.

Guías Clínicas - SEOM: Sociedad Española de Oncología Médica [Internet]. [cited 2023 Jul 22]. Available from: https://seom.org/publicaciones/guias-clinicas

24.

NCCN Guidelines. Treatment by Cancer Type [Internet]. NCCN. [cited 2023 Jul 22]. Available from: https://www.nccn.org/guidelines/category_1

25.

Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Semin Nucl Med. 2017;47:143–57.PubMedCrossRef

26.

Bar-Sever Z, Giammarile F, Israel O, Nadel H, editors. A practical guide for pediatric nuclear medicine. Berlin [Heidelberg]: Springer; 2023.

27.

Olecki E, Grant CN. MIBG in neuroblastoma diagnosis and treatment. Semin Pediatr Surg. 2019;28: 150859.PubMedCrossRef

28.

Jacobs A, Delree M, Desprechins B, Otten J, Ferster A, Jonckheer MH, et al. Consolidating the role of *I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol. 1990;20:157–9.PubMedCrossRef

29.

Lumbroso J, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Lemerle J, et al. Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 115 cases. Bull Cancer (Paris). 1988;75:97–106.PubMed

30.

SIOP Europe. The European Society for Paediatric Oncology. High-risk neuroblastoma. Standard clinical practice recommendations 2020. [Internet]. [cited 2023 May 16]. Available from: https://siope.eu/media/documents/escp-high-risk-neuroblastoma-standard-clinical-practice-recommendations.pdf

31.

Liu B, Servaes S, Zhuang H. SPECT/CT MIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma. Clin Nucl Med. 2018;43:232–8.PubMedCrossRef

32.

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting. J Clin Oncol. 2017;35:2580–7.PubMedPubMedCentralCrossRef

33.

Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, et al. Integrated imaging using MRI and ¹²³ | metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. Am J Roentgenol. 2003;181:1115–24.CrossRef

34.

Ladenstein R, Lambert B, Pötschger U, Castellani M-R, Lewington V, Bar-Sever Z, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45:292–305.PubMedCrossRef

35.

Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, et al. Validation of postinduction curie scores in high-risk neuroblastoma: a Children’s oncology group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59:502–8.PubMedPubMedCentralCrossRef

36.

Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. J Nucl Med. 2013;54:541–8.PubMedCrossRef

37.

Rubio PM, Galán V, Rodado S, Plaza D, Martínez L. MIBG therapy for neuroblastoma: precision achieved with dosimetry, and concern for false responders. Front Med. 2020;7:173.CrossRef

38.

Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JCA, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784–90.PubMedCrossRef

39.

Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, et al. A new 123I-MIBG whole body scan scoring method–application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer Oxf Engl. 1990;1995(31A):256–61.

40.

Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJB, et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel. Eur J Nucl Med Mol Imaging. 2017;44:234–41.PubMedCrossRef

41.

Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319–26.PubMedPubMedCentralCrossRef

42.

Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiogr Rev Publ Radiol Soc N Am Inc. 2016;36:258–78.

43.

Melzer HI, Coppenrath E, Schmid I, Albert MH, Von Schweinitz D, Tudball C, et al. 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011;38:1648–58.PubMedCrossRef

44.

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601.PubMedCrossRef

45.

States LJ, Reid JR. Whole-body PET/MRI applications in pediatric oncology. Am J Roentgenol. 2020;215:713–25.CrossRef

46.

Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. New PET radiotracers for the imaging of neuroendocrine neoplasms. Curr Treat Options Oncol. 2022;23:703–20.PubMedPubMedCentralCrossRef

47.

Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.PubMedCrossRef

48.

Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–97.PubMedPubMedCentralCrossRef

49.

INRG Staging System | International Neuroblastoma Risk Group Task Force [Internet]. [cited 2023 May 14]. Available from: https://inrgdb.org/neuroblastoma-information/staging-system/

50.

Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298–303.PubMedPubMedCentralCrossRef

51.

Littooij AS, De Keizer B. Imaging in neuroblastoma. Pediatr Radiol. 2022;53:783–7.PubMedPubMedCentralCrossRef

52.

Lanza C, Galeazzi V, Carboni N, De Berardinis A, De Marino L, Barile A, et al. Neuroblastoma image-defined risk factors in adrenal neuroblastoma: role of radiologist. Gland Surg. 2019;8:S168–77.PubMedPubMedCentralCrossRef

53.

Sokol E, Desai A. The evolution of risk classification for neuroblastoma. Children. 2019;6:27.PubMedPubMedCentralCrossRef

54.

Lin KS, Uemura S, Thwin KKM, Nakatani N, Ishida T, Yamamoto N, et al. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood. Transl Oncol. 2021;14: 101019.PubMedPubMedCentralCrossRef

55.

INRG Classification System | International Neuroblastoma Risk Group Task Force [Internet]. [cited 2023 Jul 25]. Available from: https://inrgdb.org/neuroblastoma-information/classification-system/

56.

Instituto de Investigacion Sanitaria La Fe. European Low and Intermediate Risk Neuroblastoma Protocol [Internet]. clinicaltrials.gov; 2019 Oct. Report No.: NCT01728155. Available from: https://clinicaltrials.gov/study/NCT01728155

57.

Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GAM, et al. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 2017;123:1095–105.PubMedCrossRef

58.

Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, et al. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2023;70: e30418.PubMedPubMedCentralCrossRef

59.

Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with Stage 4 neuroblastoma: results of the cologne interscore comparison study. J Clin Oncol. 2013;31:944–51.PubMedCrossRef

60.

EVICORE. Pediatric Oncology Imaging Guidelines Version 1.0. 2021 [Internet]. [cited 2023 May 16]. Available from: https://www.evicore.com/-/media/files/evicore/clinical-guidelines/evicore_pedoncology_v10_final_eff010121_pub110520.pdf

61.

SIOP Europe. The European Society for Paediatric Oncology. Low-risk neuroblastoma. Standard clinical practice recommendations 2021. [Internet]. [cited 2023 Nov 9]. Available from: https://siope.eu/media/documents/low-risk-neuroblastoma-standard-clinical-practice-recommendations.pdf

62.

Morgenstern D, Barone G, Moreno L, Anderson J, Brock P, Elliott M, et al. Options for the treatment of patients with relapsed/progressive high-risk neuroblastoma. 2015;2.

63.

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. Jpn J Clin Oncol. 2018;48:214–41.PubMedCrossRef

64.

Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, et al. 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klin Padiatr. 2017;229:147–67.PubMedCrossRef

65.

Children’s Cancer and Leukaemia Group (CCLG). Neuroblastoma Special Interest Group. Low and Intermediate Risk Neuroblastoma Treatment Guidelines (2020) [Internet]. [cited 2023 Nov 9]. Available from: https://www.cclg.org.uk/write/MediaUploads/Member%20area/Treatment%20guidelines/LIRNB_Guidelines_Feb_2020_Final.pdf

66.

St. Anna Kinderkrebsforschung. High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) [Internet]. clinicaltrials.gov; 2020 Oct. Report No.: NCT01704716. Available from: https://clinicaltrials.gov/study/NCT01704716

67.

Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 6.0 - October 2023 [Internet]. [cited 2023 Dec 13]. Available from: http://www.survivorshipguidelines.org/pdf/2023/COG_LTFU_Guidelines_Comprehensive_v6.pdf

68.

DuBois SG, Macy ME, Henderson TO. High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2022;42:1–13.

69.

Yi ES, Son MH, Hyun JK, Cho HW, Ju HY, Lee JW, et al. Predictors of survival in patients with high-risk neuroblastoma who failed tandem high-dose chemotherapy and autologous stem cell transplantation. Pediatr Blood Cancer. 2020;67: e28066.PubMedCrossRef

70.

Gauthé M, Breton M, Jehanno N, Cellier C, Michon J, Sarnacki S, et al. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site. Q J Nucl Med Mol Imaging. 2020;64:131–8.PubMedCrossRef

71.

Seo ES, Shin M, Lim H, Cho HW, Ju HY, Cho Y-S, et al. Clinical implication of residual MIBG-positive disease in the follow-up of high-risk neuroblastoma treated with tandem high-dose chemotherapy and autologous stem cell transplantation. Pediatr Blood Cancer. 2022;69: e29502.PubMedCrossRef

72.

Man S, Yan J, Li J, Cao Y, Hu J, Ma W, et al. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma. Int J Med Sci. 2021;18:1857–65.PubMedPubMedCentralCrossRef

73.

Hu R, Zhang Y, Liu S, Lee P, Liu C, Liu A. Prognostic prediction by 18F-FDG-PET/CT parameters in patients with neuroblastoma: a systematic review and meta-analysis. Front Oncol. 2023;13:1208531.PubMedPubMedCentralCrossRef

74.

Feng L, Zhang S, Wang C, Li S, Kan Y, Wang C, et al. Axial skeleton radiomics of 18F-FDG PET/CT: impact on event-free survival prediction in high-risk pediatric neuroblastoma. Acad Radiol. 2023;30:2487–96.PubMedCrossRef

75.

AEMPS. Solución de lugol fuerte [Internet]. [cited 2024 Jan 18]. Available from: https://www.aemps.gob.es/formulario-nacional/monografias/formulas-magistrales-tipificadas/fn_2003_fmt_018.pdf?x40380

76.

AEMPS. CIMA: MIBG (123I) CURIUM PHARMA SPAIN 74 MBq/ml SOLUCION INYECTABLE [Internet]. [cited 2023 May 14]. Available from: https://cima.aemps.es/cima/dochtml/ft/68724/FT_68724.html

77.

Jacobson AF, Travin MI. Impact of medications on mIBG uptake, with specific attention to the heart: comprehensive review of the literature. J Nucl Cardiol. 2015;22:980–93.PubMedCrossRef

78.

Tratado de medicina nuclear en la práctica clínica. Carlos Andrés Achury Murcia; Ana María García Vicente, Josep Martin Comin, Angel Soriano Castrejón. Grupo Aula Médica S.L., 2019 (3 ed.). ISBN 978-84-7885-661-9.

79.

Gelfand MJ, Parisi MT, Treves ST. Pediatric Nuclear Medicine Dose Reduction Workgroup. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med. 2011;2011(52):318–22.CrossRef

80.

Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, et al. SNMMI procedure standard/EANM practice guideline on pediatric 18 F-FDG PET/CT for oncology 1.0. J Nucl Med. 2021;62:99–110.PubMedPubMedCentralCrossRef

81.

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.PubMedCrossRef

82.

Quantitative Imaging Biomarkers Alliance. Quantitative FDG-PET Technical Committee. UPICT oncology FDG-PET CT protocol. [Internet]. [cited 2024 Sep 26]. Available from: https://qibawiki.rsna.org/images/7/71/UPICT_Oncologic_FDG-PETCTProtocol_Dec-2014a.pdf

83.

AEMPS. CIMA: FLUORSCAN 3000 MBq/ml SOLUCION INYECTABLE [Internet]. [cited 2023 May 14]. Available from: https://cima.aemps.es/cima/publico/detalle.html?nregistro=68293

84.

AEMPS. CIMA: FLUOTRACER, 1110 MBq/ml, SOLUCION INYECTABLE [Internet]. [cited 2023 May 14]. Available from: https://cima.aemps.es/cima/publico/detalle.html?nregistro=64781

85.

AEMPS. CIMA: IRABGLU 370 MBQ/ML SOLUCION INYECTABLE [Internet]. [cited 2023 May 14]. Available from: https://cima.aemps.es/cima/publico/detalle.html?nregistro=82947

86.

Padma S, Sundaram PS, Tewari A. PET/CT in paediatric malignancies - an update. Indian J Med Paediatr Oncol. 2016;37:131–40.PubMedPubMedCentralCrossRef

87.

Kroiss AS. Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease. Wien Med Wochenschr. 1946;2019(169):25–32.

88.

Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57–71.PubMedCrossRef

89.

European Nuclear Medicine Guide [Internet]. [cited 2023 Nov 7]. Available from: https://www.nucmed-guide.app/#!/chapter/338

90.

Unidad de Evaluación de Tecnologías Sanitarias de Madrid. [Internet]. [cited 2023 May 14]. Available from: http://www.madrid.org/bvirtual/BVCM050332.pdf

91.

Samim A, Blom T, Poot AJ, Windhorst AD, Fiocco M, Tolboom N, et al. [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1146–57.PubMedCrossRef

92.

Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.PubMedCrossRef

93.

Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J, et al. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023;50:3097–106.PubMedCrossRef

Title: Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma
Authors: Raquel Sánchez-Vañó
Julia Balaguer
Isabel Borrego-Dorado
Alba Esteban-Figueruelo
Cristina Gámez
Raquel Hladun
Ricardo López-Almaraz
Mercedes L. Llempén
Sonia Rodado
Pedro M. Rubio-Aparicio
Publication date: 07-11-2024
Publisher: Springer International Publishing
Keywords: Neuroblastoma
Neuroblastoma
Positron Emission Tomography
Computed Tomography
Computed Tomography
Scintigraphy
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-024-03755-3

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote series | Spotlight on menopause

Springer Medicine

Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma

Abstract

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma